Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Daré Bioscience	$2.88 -1.0%	$2.93	$2.67 ▼ $7.56	$25.49M	1.2	38,840 shs	10,783 shs
EDSA Edesa Biotech	$1.98 -3.4%	$2.35	$1.55 ▼ $5.59	$13.91M	0.55	490,310 shs	40,661 shs
MNPR Monopar Therapeutics	$35.10 -11.0%	$36.80	$1.72 ▼ $54.30	$214.64M	1.11	359,271 shs	24,247 shs
PTI Proteostasis Therapeutics		$11.24	$0.87 ▼ $2.72	$37.57M	1.16	1.04 million shs	9,405 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Daré Bioscience	0.00%	-2.35%	-1.02%	-6.13%	-21.90%
EDSA Edesa Biotech	0.00%	-13.32%	-8.89%	+5.89%	-55.53%
MNPR Monopar Therapeutics	0.00%	-11.79%	+13.67%	-23.57%	+1,080.01%
PTI Proteostasis Therapeutics	0.00%	0.00%	0.00%	0.00%	+29.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Daré Bioscience	2.0097 of 5 stars	3.3	5.0	0.0	0.0	2.2	0.0	0.0
EDSA Edesa Biotech	2.9822 of 5 stars	3.5	5.0	0.0	0.0	2.2	1.7	0.6
MNPR Monopar Therapeutics	2.9532 of 5 stars	3.4	5.0	0.0	0.0	2.8	2.5	0.0
PTI Proteostasis Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Daré Bioscience	2.67	Moderate Buy	$24.00	733.33% Upside
EDSA Edesa Biotech	3.00	Buy	$21.00	960.61% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	57.64% Upside
PTI Proteostasis Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MNPR, DARE, PTI, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00
3/13/2025	EDSA Edesa Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Daré Bioscience	$9.78K	2,605.07	N/A	N/A	($0.61) per share	-4.72
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.18 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A
PTI Proteostasis Therapeutics	$5M	0.00	N/A	N/A	$1.22 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Daré Bioscience	-$30.16M	-$0.51	N/A	N/A	N/A	-191.65%	N/A	-18.98%	5/13/2025 (Estimated)
EDSA Edesa Biotech	-$6.17M	-$1.87	N/A	N/A	N/A	N/A	-233.69%	-124.14%	N/A
MNPR Monopar Therapeutics	-$8.40M	-$3.60	N/A	N/A	N/A	N/A	-107.21%	-87.57%	N/A
PTI Proteostasis Therapeutics	-$59.13M	-$1.16	N/A	N/A	N/A	N/A	-75.39%	-55.04%	N/A

Latest MNPR, DARE, PTI, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
2/14/2025	Q1 2025	EDSA Edesa Biotech	-$0.31	-$0.48	-$0.17	-$0.48	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PTI Proteostasis Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Daré Bioscience	N/A	1.14	1.14
EDSA Edesa Biotech	N/A	1.09	0.91
MNPR Monopar Therapeutics	N/A	5.41	5.41
PTI Proteostasis Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Daré Bioscience	6.70%
EDSA Edesa Biotech	5.50%
MNPR Monopar Therapeutics	1.83%
PTI Proteostasis Therapeutics	16.64%

Insider Ownership

Company	Insider Ownership
DARE Daré Bioscience	4.00%
EDSA Edesa Biotech	22.60%
MNPR Monopar Therapeutics	34.90%
PTI Proteostasis Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
EDSA Edesa Biotech	20	7.02 million	2.60 million	Not Optionable
MNPR Monopar Therapeutics	10	6.12 million	3.97 million	Not Optionable
PTI Proteostasis Therapeutics	44	52.19 million	N/A	Not Optionable

MNPR, DARE, PTI, and EDSA Headlines

Recent News About These Companies

Unlocking proteostasis: A new frontier in the fight against neurodegenerative diseases like Alzheimer's

January 3, 2025 | msn.com

Proteostasis modulates gene dosage evolution in antibiotic-resistant bacteria

October 31, 2024 | elifesciences.org

DELE1 maintains muscle proteostasis to promote growth and survival in mitochondrial myopathy

October 8, 2024 | embopress.org

Islamabad on red alert as PTI all set to hold rally today

September 9, 2024 | thenews.com.pk

‘PTI was not a party in reserved seats case’: SC judges issue dissenting opinion

August 9, 2024 | tribune.com.pk

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

April 24, 2024 | globenewswire.com

News From PTI

April 11, 2024 | health.economictimes.indiatimes.com

PTI files petition in ECP for disqualification of Faryal Talpur

April 8, 2024 | radio.gov.pk

SC accepts ECP’s appeal, strips PTI of ‘bat’ symbol

March 25, 2024 | radio.gov.pk

Independent candidates continue to join PTI in center, Punjab

March 12, 2024 | radio.gov.pk

Peshawar High Court lifts stay on ECP verdict nullifying PTI’s intra-party poll

January 30, 2024 | radio.gov.pk

Experts hail decision of ECP that PTI received funding from prohibited sources

January 13, 2024 | radio.gov.pk

Former PTI Chairman admits recent article in Economist not written by him, AI generated

January 13, 2024 | radio.gov.pk

ECP declares PTI’s intra-party polls as null and void

January 10, 2024 | radio.gov.pk

Qureshi barred, many PTI leaders cleared to contest polls

January 8, 2024 | pakistantoday.com.pk

Pakistan’s ex-PM Imran and PTI party most popular in the country: Poll

January 4, 2024 | gulftoday.ae

As scrutiny ends, PTI faces ‘unprecedented wave’ of rejections of nominations

January 1, 2024 | pakistantoday.com.pk

PTI berates ECP over irresponsible, nonsensical statement regarding judiciary

December 30, 2023 | pakistantoday.com.pk

PTI to play its election innings ‘without bat’ on tough pitch

December 25, 2023 | gulftoday.ae

PTI core committee urges ECP to allocate ‘bat’ symbol

December 17, 2023 | pakistantoday.com.pk

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
By Sam Quirke | April 30, 2025
View Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged
Time to Buy Alibaba and PDD After Tariff Exemptions?
By Gabriel Osorio-Mazilli | April 17, 2025
View Time to Buy Alibaba and PDD After Tariff Exemptions?
3 High-Yield Dividend Stocks on Sale After Wild Market Swing
By Nathan Reiff | April 14, 2025
View 3 High-Yield Dividend Stocks on Sale After Wild Market Swing
Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
By Jeffrey Neal Johnson | April 27, 2025
View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery
Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally
By Gabriel Osorio-Mazilli | April 17, 2025
View Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally

MNPR, DARE, PTI, and EDSA Company Descriptions

Daré Bioscience NASDAQ:DARE

$2.88 -0.03 (-1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.89 +0.01 (+0.35%)

As of 05:16 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Edesa Biotech NASDAQ:EDSA

$1.98 -0.07 (-3.41%)

Closing price 03:57 PM Eastern

Extended Trading

$2.02 +0.04 (+2.27%)

As of 04:05 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Monopar Therapeutics NASDAQ:MNPR

$35.10 -4.32 (-10.96%)

Closing price 04:00 PM Eastern

Extended Trading

$35.50 +0.40 (+1.14%)

As of 06:54 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Proteostasis Therapeutics NASDAQ:PTI

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time